Redhill Biopharma Ltd
RDHL
查看详细走势图
1.070USD
+0.040+3.88%
收盘 02/06, 16:00（美东）报价延迟15分钟
3.56M总市值
0.02市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.88%
5天
-12.30%
1月
-12.30%
6月
-8.55%
今年开始到现在
+3.88%
1年
-80.55%
查看详细走势图
TradingKey Redhill Biopharma Ltd股票评分
单位: USD 更新时间: 2026-02-06操作建议
Redhill Biopharma Ltd当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名130/159位。机构持股占比较高，近一个月，市场表现非常差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Redhill Biopharma Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Redhill Biopharma Ltd亮点
亮点风险
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
业绩增长期
公司处于发展阶段，最新年度总收入8.04M美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值高估
公司最新PE估值0.02，处于3年历史高位
机构减仓
最新机构持股28.22K股，环比减少68.06%
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Redhill Biopharma Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Redhill Biopharma Ltd简介
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
公司代码RDHL
公司Redhill Biopharma Ltd
CEOBen-Asher (Dror)
网址https://www.redhillbio.com/
相关品种
